Monte Rosa Therapeutics GLUE 深 沪
已收盘 12-12 16:00:00 美东时间
16.31
-0.250
-1.51%
华盛通- 最 高16.85
- 今 开16.56
- 成交量 55.91万股
- 最 低 16.2417
- 昨 收 16.56
- 总市值 10.62亿
- 52周最高 18.15
- 市盈率 静 --
- 换手率 0.86%
- 52周最低 3.5001
- 委 比 96.92%
- 总股本 6511.78万
- 历史最高 45.56
- 量 比 0.71
- 振 幅 3.67%
- 历史最低 2.44
- 每 手 1
- 风险率 3.36%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 17:17
Reported Saturday, Monte Rosa Therapeutics Presents Preclinical Data At AHA 2025 Demonstrating MRT-8102 NEK7-Directed Molecular Glue Degrader Modulates NLRP3 Inflammasome In Cardiovascular And Cardiometabolic Diseases
Data support NEK7 as a potential novel and differentiated therapeutic approach to modulate the NLRP3 inflammasome in multiple cardiovascular and cardiometabolic diseases, including pericarditis and atherosclerosisInitial
11-10 17:03
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 10:22
Monte Rosa Therapeutics Q3 Sales $12.768M Beat $5.420M Estimate
Monte Rosa Therapeutics (NASDAQ:GLUE) reported quarterly sales of $12.768 million which beat the analyst consensus estimate of $5.420 million by 135.57 percent. This is a 38.54 percent increase over sales of $9.216
11-06 20:24
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
Monte Rosa Therapeutics, Inc. CEO Markus Warmuth will participate in fireside chats at four investor conferences in November and December 2025. Sessions include the Guggenheim Healthcare Innovation Conference in Boston on November 10, TD Cowen Immunology & Inflammation Summit virtually on November 13, Jefferies Global Healthcare Conference in London on November 18, and Piper Sandler Healthcare Conference in New York on December 2. Webcasts will b...
11-03 12:00
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2025 on the Potential of MRT-6160, a VAV1-directed Molecular Glue Degrader, to Treat Immune-mediated Diseases
Monte Rosa Therapeutics announced preclinical data for MRT-6160, a molecular glue degrader targeting VAV1, showing potential to treat autoimmune and inflammatory diseases like lupus, Sjögren’s syndrome, and rheumatoid arthritis. MRT-6160 significantly reduced disease markers in a mouse model and outperformed existing therapies. The drug, developed with Novartis, is advancing towards Phase 2 studies, with Monte Rosa eligible for up to $2.1 billion...
10-24 11:00
Why Webtoon Entertainment Shares Are Trading Higher By 48%; Here Are 20 Stocks Moving Premarket
Shares of Webtoon Entertainment Inc (NASDAQ:WBTN) rose sharply in pre-market tr...
09-16 17:41
美股牛股 | 贝利石油大涨21%，与CRC达成合并协议；稀土概念股AREC涨超20%
C4 Therapeutics涨超34%，大行升其目标价至6美元；贝利石油大涨21%，与CRC达成合并协议；稀土概念股AREC涨超20%>>
09-16 15:15
道指开盘涨0.1%，标普500涨0.3%，纳指涨0.5%
德州仪器跌3.8%，ADI跌2.6%，中国对源自美国的部分模拟芯片启动反倾销调查。英伟达跌1.3%，违反中国反垄断法，将被进一步调查。特斯拉涨7.6%，马斯克斥...
09-15 21:30
Monte Rosa’s Stock (GLUE) Skyrockets on $5.7B Deal with Novartis
Swiss giant drug producer Novartis ($NVS) has found a new destination for its r...
09-15 21:26
